Accolade Results Presentation Deck

6 Fiscal Year '23 Preview ■ Accolade One and Accolade Care first go-lives on 1/1 Expansion in customers, members, partners, health plans 25% revenue growth and reduction in Adjusted EBITDA loss Target $600m in Revenue and Breakeven in FY25 Revenue vs Adjusted EBITDA (Loss) as a % of Revenue* ($ in millions) 77 -56% FY18 95 -41% FY19 133 -25% FY20 170 -16% FY21 $306- $309* -16% FY22 25% Growth* -11% FY23 *Adjusted EBITDA (Loss) excludes depreciation and amortization, acquisition and integration-related costs, stock-based compensation, and change in fair value of contingent consideration. See Appendix for disclosures and reconciliations related to preliminary guidance for fiscal years ending February 28, 2022 and 2023

View entire presentation